Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 PS2-13-01 | DOI: 10.1530/endoabs.101.PS2-13-01

1Hospital de Clínicas de Porto Alegre, Thyroid Section, Endocrinology Division, Porto Alegre, Brazil; 2Hospital Nossa Senhora Da Conceição, Brazil; 3Hospital de Clínicas de Porto Alegre, Brazil


Introduction: Medullary thyroid carcinoma (MTC) is a rare malignant tumor that originates from the thyroid C cells. MTC may occur sporadically (75%) or as part of cancer syndrome (hMTC). hMTC is associated with germline mutations in the RET proto-oncogene. The pathogenic variants at codon 634 were the most prevalent (30-50%). Other pathogenic variants were found in less than 10% of MEN2A subjects. The rare RET variant p. Ser904Phe has been reported in only 3 kindreds worldwide and is currently classified as likely pathogenic. Objectives: To characterize the clinical and molecular features of the MEN 2A kindred with a variant at codon 904 and investigate its penetrance and risk of progression.

Methods: Ascending, collateral, and descending relatives of subjects with p. Ser904Phe variant were invited to participate in this study. Molecular analysis was performed by Sanger sequencing of RET exon 15.

Results: Of the 48 individuals screened, 31 (64.5%) harbored the mutation: 17 (54%) were women, and the median age was 34.4 ± 15.7 years. Thyroid ultrasound was performed on 24 subjects, revealing a nodule in 12 of them (0.8 ± 0.46 cm). All participants with thyroid nodules had high calcitonin levels (reference value up to 5ng/l). Twelve patients underwent total thyroidectomy (7 women and 5 men): 10 presented MTC (mean 1.06 cm), 1 had mixed MTC and papillary carcinoma carcinoma (1.2 cm), and 1 had C cell hyperplasia with amyloid deposits (0.1 cm). Gene carriers without any evidence of clinical disease are being monitored. Twelve relatives are awaiting sample collection for molecular screening. Conclusions: This large hereditary MTC kindred with rare RET variant p. Ser904Phe indicate that this variant is associate with low aggressive tumor. Furthermore, the strong genotype-phenotype association indicate that it must be reclassified as pathogenic variant rather than likely pathogenic. Follow-up of these subjects will be necessary for a better understanding of the long-term behavior of the disease in carriers of this rare variant.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.